The matrix gamma-carboxyglutamate protein(MGP),a vitamin K-dependent protein,inhibits arte-rial calcification.The substance's ability to inhibit calcification is linked to its post-translational modifications,specifical-ly γ-glutamyl carboxylation and phosphorylation.The molecular mechanism of the calcification inhibitor remains unclear due to its low solubility and complicated post-translational modifications.In this section,we summarize current research and ongoing debates about post-translational modifications of MGP and its mechanism for inhibiting calcification.We re-viewed recent research on diseases associated with MGP deficiency,such as cardiovascular disease,chronic kidney dis-ease,and Keutel syndrome.Hopefully,this review can help us understand how MGP functions as a vascular calcification inhibitor and identify potential treatments for diseases resulting from its dysfunction.

The matrix gamma-carboxyglutamate protein(MGP),a vitamin K-dependent protein,inhibits arte-rial calcification.The substance's ability to inhibit calcification is linked to its post-translational modifications,specifical-ly γ-glutamyl carboxylation and phosphorylation.The molecular mechanism of the calcification inhibitor remains unclear due to its low solubility and complicated post-translational modifications.In this section,we summarize current research and ongoing debates about post-translational modifications of MGP and its mechanism for inhibiting calcification.We re-viewed recent research on diseases associated with MGP deficiency,such as cardiovascular disease,chronic kidney dis-ease,and Keutel syndrome.Hopefully,this review can help us understand how MGP functions as a vascular calcification inhibitor and identify potential treatments for diseases resulting from its dysfunction.

Objective To explore the verification methods for the performance of quantitative detection kit of anti-dsDNA antibodiy with enzyme-linked immunosorbent assay (ELISA).Methods The precision was verified according to the EP15-A2 document approved by the American Clinical and Laboratory Standards Institute(CLSI).The accuracy was verified by detecting the samples of previous external quality evaluation(EQA),compared with the comparative kits and recovery test.The lower limit of detection(LLD) was calculated by the results of blank samples.The cut-off value was verified according to the C28-A3C document approved by CLSI and CNAS-CL39:Guidance on the Application of Accreditation Criteria for the Medical Laboratory Quality and Competence in the Field of Clinical Qualitative Immunology respectively.The improved Doumas method was used to verify the range of linearity.Results The measured intra-assay and inter-assay coefficients of variation were lower than those announced by the manufacturer or the calculated values according to the EP15-A2 document.The coincidence rates for negative and positive EQA samples between detected and expected values were 98.4％ (63/64) and 100％ (20/20) respectively.The total coincidence rate was 98.8％ (83/84).The coincidence rate for negative and positive samples between the results from candidate and comparative kits were 91.2％ (52/57) and 87.0％ (40/46) respectively.The total coincidence rate was 89.3％ (92/103) and the Kappa value was 0.783 (P =0.062),which implied excellent consistency between the two kits.The mean recovery rate was 99.65％.The measured LLD was 0.5 IU/mL which was lower than 1 IU/mL as claimed by the manufacturer.The measured cut-off value according to the CNAS-CL39 document was 18.51 IU/mL,which was close to 20 IU/mL announced by the manufacturer.Based on the C28-A3C method,the cut-off value could be approved.The linear regression equation was Y =0.978 8X-3.125 4,r2 =0.996 1.There was no statistical difference between the intercept (-3.125 4) and 0 (t =-0.772,P =0.483).The range of linearity was from 1.6 to 212.5 IU/mL,which was consistent with the values declared by the manufacturer.All the verifications of the five performances above-mentioned could be passed.Conclusion The precision,accuracy,LLD,cut-off value and range of linearity of the candidate quantitative ELISA kit for anti-dsDNA antibody were consistent with the statement of the manufacturer,which indicated the performance of the kits may meet the requirements of clinic diagnosis and treatment.A series of methods used in this study provided a simple protocol for verifying the performance of quantitative ELISA kits.